



New US patent approval for Episurf Medical

Episurf Medical (NASDAQ: EPIS B) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent. The patent, entitled “*Metatarsal implant*”, relates to the big toe implant that the company has developed. This is the first approval within this patent family.

“This patent gives us protection in the US within the field of implants for the metatarsal bone of the toe. This relates to the Episealer® MTP implant for the big toe that the company has developed, a product that is currently undergoing a review process at the US FDA. We are delighted to get this patent in place, as part of our preparations for US market launch of our big toe implant” comments Katarina Flodström, Deputy CEO, Episurf Medical.

For more information, please contact:

Katarina Flodström, Deputy CEO, Episurf Medical
Tel: +46 707 38 35 70
Email: katarina.flodstrom@episurf.com

About Episurf Medical

Episurf Medical is a newly created real estate company with exposure to a diversified portfolio of real estate assets. The Company aims to deliver expansive value creation through Nordic yielding properties, with a focus on commercial and industrial buildings. The company also has a medical technology business which is based on the individualised implant Episealer® and related surgical instruments, which are used for treating cartilage damage in joints. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, visit the company’s website: www.episurf.com.

The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 25 February 2026.